Lexeo Therapeutics - LXEO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.80
  • Forecasted Upside: 72.04%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$12.09
▼ -0.14 (-1.14%)

This chart shows the closing price for LXEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lexeo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LXEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LXEO

Analyst Price Target is $20.80
▲ +72.04% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lexeo Therapeutics in the last 3 months. The average price target is $20.80, with a high forecast of $23.00 and a low forecast of $19.00. The average price target represents a 72.04% upside from the last price of $12.09.

This chart shows the closing price for LXEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Lexeo Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/17/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2023Leerink PartnrsReiterated RatingOutperformLow
11/28/2023JPMorgan Chase & Co.Initiated CoverageOverweight$20.00Low
11/28/2023Stifel NicolausInitiated CoverageBuy$20.00Low
11/28/2023Royal Bank of CanadaInitiated CoverageOutperform$22.00Low
11/28/2023SVB LeerinkInitiated CoverageOutperform$19.00Low
11/28/2023Chardan CapitalInitiated CoverageBuy$23.00Low
(Data available from 4/16/2019 forward)

News Sentiment Rating

-0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Lexeo Therapeutics logo
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More

Today's Range

Now: $12.09
Low: $11.73
High: $12.25

50 Day Range

MA: $14.98
Low: $12.09
High: $17.00

52 Week Range

Now: $12.09
Low: $9.00
High: $22.33

Volume

105,400 shs

Average Volume

103,218 shs

Market Capitalization

$398.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lexeo Therapeutics?

The following sell-side analysts have issued research reports on Lexeo Therapeutics in the last year: Chardan Capital, JPMorgan Chase & Co., Leerink Partnrs, Royal Bank of Canada, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for LXEO.

What is the current price target for Lexeo Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Lexeo Therapeutics in the last year. Their average twelve-month price target is $20.80, suggesting a possible upside of 72.0%. Chardan Capital has the highest price target set, predicting LXEO will reach $23.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $19.00 for Lexeo Therapeutics in the next year.
View the latest price targets for LXEO.

What is the current consensus analyst rating for Lexeo Therapeutics?

Lexeo Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LXEO will outperform the market and that investors should add to their positions of Lexeo Therapeutics.
View the latest ratings for LXEO.

What other companies compete with Lexeo Therapeutics?

Other companies that are similar to Lexeo Therapeutics include Metagenomi, Monte Rosa Therapeutics, Humacyte, Invivyd and MeiraGTx. Learn More about companies similar to Lexeo Therapeutics.

How do I contact Lexeo Therapeutics' investor relations team?

Lexeo Therapeutics' physical mailing address is 345 Park Avenue South, 6th Floor, New York, NY 10010, United States. The company's listed phone number is 212-547-9879 and its investor relations email address is [email protected]. The official website for Lexeo Therapeutics is www.lexeotx.com. Learn More about contacing Lexeo Therapeutics investor relations.